Huons-Biosyn Sign MOU for Domestic Rights of Immuno-Oncology Drug 'Imucotel'

[Asia Economy Reporter Cho Hyun-ui] Huons announced on the 22nd that it has signed a business agreement with Biosyn Korea to secure the domestic distribution rights for the bladder cancer recurrence prevention immuno-oncology drug 'Imucotel®.'

Through clinical trials, Imucotel® has been confirmed to have superior therapeutic effects compared to existing bladder cancer drugs such as BCG vaccine and anticancer agents, while showing no resistance or toxicity.

The main ingredient is immunocyanin, which is stably isolated and purified from KLH (hemocyanin of the keyhole limpet) through Biosyn's patented method before production.

When immunocyanin in Imucotel® is injected, the human body activates immune regulatory functions against exogenous antigen determinants, thereby activating antibody production.

In particular, the surface of immunocyanin contains the bladder cancer antigen ‘TF antigen,’ which induces the production of antibodies against the TF antigen and acts as a cancer vaccine by lysing cancer cells through antigen-antibody reactions.

Huons plans to strengthen sales and marketing in urology departments of general hospitals, starting with securing the domestic distribution rights for Imucotel®. Additionally, they aim to establish the combination therapy of Imucotel® and Selenase® as a new paradigm in immunotherapy.

Um Ki-an, CEO of Huons, stated, “We will strive to enable patients suffering from various diseases affected by the TF antigen, not only bladder cancer, to receive more effective treatment through the combined immunotherapy of Imucotel® and Selenase®.”

This content was produced with the assistance of AI translation services.